These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 590287)

  • 1. 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations.
    Aubert C; Rosengren E; Rorsman H; Rouge F; Foa C; Lipcey C
    Eur J Cancer (1965); 1977 Nov; 13(11):1299-308. PubMed ID: 590287
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diagnosis of amelanotic malignant melanoma by means of the fluorescence method (Falck & Hillarp) and determination of 5-S-cysteinyldopa in the lesions].
    Morishima T; Fukada E; Nagashima N
    Nihon Hifuka Gakkai Zasshi; 1983 Jan; 93(1):51-4. PubMed ID: 6408288
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
    Mojamdar M; Ichihashi M; Mishima Y
    J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
    [No Abstract]   [Full Text] [Related]  

  • 4. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
    Sameshima T; Morishima T
    Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
    Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Definitive diagnosis of early malignant melanoma lesions by the quantitative analysis of 5-S-cysteinyldopa in the tissue and touch fluorescence method].
    Kanematsu S; Morishima T
    Nihon Hifuka Gakkai Zasshi; 1989 Jun; 99(7):783-91. PubMed ID: 2511360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
    Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular distribution of dopa and 5-S-cysteinyldopa in Harding-Passey melanoma.
    Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1977; 57(4):313-5. PubMed ID: 70922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contents of cysteinyldopa isomers and DOPA in lesions of malignant melanoma (author's transl)].
    Morishima T; Saito M; Fujita M; Fukada E; Nagashima N; Hanawa S
    Nihon Hifuka Gakkai Zasshi; 1982 Feb; 92(2):157-9. PubMed ID: 6806514
    [No Abstract]   [Full Text] [Related]  

  • 11. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
    Marnot D; Decaux F; Berthelot P; Kalis B; Jardillier JC; Warren L
    Cancer Detect Prev; 1983; 6(1-2):303-10. PubMed ID: 6411338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary evaluation of 5-S-cysteinyldopa and seric evaluation of IgG4 subclass during follow-up of 27 primitive malignant melanomas (author's transl)].
    Cesarini JP; Daveau M; Picard F; Fournier E; Rivat L; Rivat C
    Ann Dermatol Venereol; 1978 Apr; 105(4):405-8. PubMed ID: 686614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
    Inoi T; Mojamdar M; Ichihashi M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1984 Jan; 94(1):39-43. PubMed ID: 6433083
    [No Abstract]   [Full Text] [Related]  

  • 14. [Excretion of 5-S-cysteinyldopa in the urine of Japanese patients with malignant melanoma--a helpful biochemical marker for assessing the progression of disease].
    Hanawa S
    Nihon Hifuka Gakkai Zasshi; 1983 Mar; 93(4):433-42. PubMed ID: 6411952
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
    Graef V; Paul E
    Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of 2-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa from the urine of patients with melanoma.
    Prota G; Rorsman H; Rosengren AM; Rosengren E
    Experientia; 1977 Jun; 33(6):720-1. PubMed ID: 891724
    [No Abstract]   [Full Text] [Related]  

  • 17. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
    Paul E; Graef V; Ruppel R
    Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
    Paul E; Graef V; Ruppel R; Hellwich M
    Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of DOPA, dopamine, and 5-S-cysteinyl-DOPA in plasma, urine, and tissue samples by high-performance liquid chromatography with electrochemical detection.
    Ito S; Kato T; Maruta K; Fujita K; Kurahashi T
    J Chromatogr; 1984 Nov; 311(1):154-9. PubMed ID: 6440898
    [No Abstract]   [Full Text] [Related]  

  • 20. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
    Ichihasi M; Mojamdar M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.